Zobrazeno 1 - 10
of 147
pro vyhledávání: '"Allan Gibofsky"'
Autor:
Alain Saraux, Licia Maria Henrique da Mota, Sanjay Dixit, Allan Gibofsky, Tsukasa Matsubara, Amy Mulvey, Cheryl Koehn, Mahta Mortezavi, Michelle Segovia, Meriem Kessouri
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 2, Pp 257-268 (2024)
Abstract Introduction The global coronavirus 2019 (COVID-19) pandemic created many challenges in healthcare provision. This study aimed to evaluate the global impact of the COVID-19 pandemic on people living with rheumatoid arthritis (RA). Methods Th
Externí odkaz:
https://doaj.org/article/aa7976799db9487fa5130b2db5dae492
Autor:
Anne R Bass, Bella Mehta, Mark Alan Fontana, Susan M Goodman, Deanna Jannat-Khah, Carine J Moezinia, Carol A Mancuso, Vinicius C Antao, Allan Gibofsky, Said Ibrahim
Publikováno v:
RMD Open, Vol 6, Iss 3 (2020)
Objective There is emerging evidence that COVID-19 disproportionately affects people from racial/ethnic minority and low socioeconomic status (SES) groups. Many physicians across the globe are changing practice patterns in response to the COVID-19 pa
Externí odkaz:
https://doaj.org/article/2ed40180f7ac4c0d92519ee0a4c014fd
Autor:
Allan Gibofsky, James Galloway, Joern Kekow, Cristiano Zerbini, Maria de la Vega, Gavin Lee, Eun Young Lee, Catalin Codreanu, Cheryl Koehn, Kathy Steinberg, Eustratios Bananis, Dario Ponce de Leon, Anna Maniccia, Ara Dikranian, for the RA NarRAtive global advisory panel
Publikováno v:
Health and Quality of Life Outcomes, Vol 16, Iss 1, Pp 1-11 (2018)
Abstract Background In order to better understand the perspectives of patients and physicians regarding the treatment and management of rheumatoid arthritis (RA), we present and compare results from a patient-based and a physician-based survey develo
Externí odkaz:
https://doaj.org/article/0e3ee8c712b14bdb969d0405849ce455
Autor:
Allan Gibofsky, Gary Jacobson, Archie Franklin, Shannan O’Hara-Levi, Laurent Peyrin-Biroulet, Melissa McGrath, Dorothy McCabe
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 29:343-349
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::83afa992a1e16ffb10d00e02a8bac8b5
https://doi.org/10.18553/jmcp.2023.29.4.343
https://doi.org/10.18553/jmcp.2023.29.4.343
Autor:
Sophie Shubow, Qin Sun, Ai Len Nguyen Phan, Dana C. Hammell, Maureen Kane, Gary H. Lyman, Allan Gibofsky, Gary R. Lichtenstein, Zachary Bloomgarden, Raymond K. Cross, Sarah Yim, James E. Polli, Yow‐Ming Wang
Publikováno v:
Clinical Pharmacology & Therapeutics. 113:37-49
The approval and adoption of biosimilar products are essential to contain increasing healthcare costs and provide more affordable choices for patients. Despite steady progress in the number of the US Food and Drug Administration (FDA) biosimilar appr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5dc4e8a450b0e5f29824c29bffbe05d9
https://doi.org/10.1002/cpt.2765
https://doi.org/10.1002/cpt.2765
Publikováno v:
The American journal of managed care. 28
Beyond the legal and regulatory limitations associated with biosimilar availability in the United States, the adoption of biosimilars is contingent on the willingness of health care providers (HCPs) to prescribe them and of patients to accept them. I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2d99287044b9d9ebbb9f94fc40ada7f4
https://pubmed.ncbi.nlm.nih.gov/36493396
https://pubmed.ncbi.nlm.nih.gov/36493396
Publikováno v:
The American journal of managed care. 28
Biosimilars hold the promise of substantial potential cost savings in health care with no compromise in the efficacy and safety of treatment. Despite this, their adoption in the United States has been substantially slower than might have been expecte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::54992296f6a3750d6be9371f550090eb
https://pubmed.ncbi.nlm.nih.gov/36493397
https://pubmed.ncbi.nlm.nih.gov/36493397
Publikováno v:
The American journal of managed care. 28
Biosimilars offer the potential to deliver substantial cost savings in biologic therapy and to contribute to increased patient access to biologic treatments, both of which are particularly relevant for immune-mediated inflammatory diseases, given the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1ecbf058edba0bc45305ca5700f4992c
https://pubmed.ncbi.nlm.nih.gov/36493395
https://pubmed.ncbi.nlm.nih.gov/36493395
Autor:
Dorothy McCabe, Allan Gibofsky
Publikováno v:
Rheumatology (Oxford, England)
Objectives We sought to evaluate perceptions of biosimilar products among US rheumatologists who prescribe TNF-α inhibitors, given that 10 TNF-α inhibitor biosimilars and two rituximab biosimilars have Food and Drug Administration (FDA) approval. M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::172c4e9b4eb95ab2d8a41cf76916ef73
http://europepmc.org/articles/PMC7850535
http://europepmc.org/articles/PMC7850535
Autor:
D. Pearce-Fisher, Allan Gibofsky, Bella Mehta, Carine J Moezinia, Said A. Ibrahim, Jane E. Salmon, Susan M. Goodman, Haley Tornberg, Deanna Jannat-Khah
Publikováno v:
JCR: Journal of Clinical Rheumatology. 26:224-228
OBJECTIVE: With hydroxychloroquine (HCQ) and chloroquine (CQ) emerging as potential therapies for coronavirus disease 2019 (COVID-19), shortages have been reported. We aimed to understand how rheumatologists, one of the most common prescribers of HCQ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::689d6b462954d129895478c1b11c2508
https://doi.org/10.1097/rhu.0000000000001539
https://doi.org/10.1097/rhu.0000000000001539